Searched for
CELLTRION
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...- Sun Pharma looks to rise in US with $10 billion Organon buyIndia's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based Organon, a sp...
- Samsung Biologics to buy US drug production facility from GSK for $280 millionSamsung Biologics is acquiring its first U.S. drug production facility from GSK for $280 million to meet long-term U.S. market demand. The ...
- Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...
- South Korean shares set to snap 4-week rally on US tariff woesSouth Korean shares experienced a significant slump on Friday, poised for their first weekly loss in five weeks, influenced by uncertaintie...
- South Korean shares hit fresh record as chip, pharma stocks rallySouth Korean shares reached a record high on Tuesday. Chipmakers saw gains due to optimism surrounding Micron Technology's upcoming results...
- Biosimilar brand buy to help Intas Pharma take on biggiesIn one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication peg...
- Big chase for a cancer drug: The urgent need for affordable Keytruda alternativesKeytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In Ind...
- Amid spike in cases, EU to shortly approve first COVID antibody drugs - sourcesThe European Medicines Agency (EMA) will this week give the green light to the treatment developed by U.S. biotech firm Regeneron and Swiss...
- EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisationTill now, only Gilead's antiviral, remdesivir, is the only COVID-19 treatment that has been approved for use in EU. Japanese regulators app...
- AstraZeneca says antibody treatment failed in preventing COVID-19 in exposed patientsThe company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the co...
- World’s longest short-selling ban coming to an endSouth Korea, like many countries around the world, banned short-selling to tame markets hit by the pandemic early last year.
- A 2020 winner in Asia’s stock market is now the biggest loserEssentially flat year-to-date, a gauge of the sector is the worst-performing in Asia, lagging the region’s benchmark by eight percentage po...
- The country with the world’s longest short-selling ban is risking a market fallKorea, whose benchmark surged last year and is up 8 per cent in 2021, this week bowed to retail investor pressure and extended the ban on t...
- Hyderabad-based Natco Pharma wants to make Eli Lilly’s Covid drugNatco has sought nod for the manufacture and marketing of baricitinib bulk drug and tablets in 1 to 4 mg versions in India. This move may t...
- These Asian stocks have benefited the most from virus crisisTo be fair, the stock market has already embraced technology and pharmaceutical shares that underpin global economic transformation.
- Seo Jung-jin: Founder who needed loan sharks is now South Korea’s second richestHis rise is extraordinary and represents a shift in the country’s business elite. While family-run conglomerates touch almost every aspect ...
- Buy Biocon, target Rs 880: Phillip Capital (India)Buy Biocon at a price target of Rs 880.
- One of the world's hottest stocks is tumbling in South KoreaIf the Celltrion skeptics are right, the stock could have a lot further to drop.
- How Dr Reddy’s is rebooting its biosimilars playDr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.
Load More
